News Release

OHSU scientists identify molecule that could help treat Parkinson’s

Discovery could immediately suggest new avenues for drug development

Peer-Reviewed Publication

Oregon Health & Science University

Haining Zhong, Ph.D., and Tianyi Mao, Ph.D.

image: Tianyi Mao, Ph.D., at left, and Haining Zhong, Ph.D., scientists with the Vollum Institute at Oregon Health & Science University, led a new study finding that adenosine effectively acts as a brake to dopamine in the brain. view more 

Credit: Oregon Health & Science University

Researchers at Oregon Health & Science University have discovered that the neurotransmitter adenosine effectively acts as a brake to dopamine, another well-known neurotransmitter involved in motor control.

Scientists found that adenosine operates in a kind of push-pull dynamic with dopamine in the brain; the discovery published today in the journal Nature.

“There are two neuronal circuits: one that helps promote action and the other that inhibits action,” said senior author Haining Zhong, Ph.D., scientist with the OHSU Vollum Institute. “Dopamine promotes the first circuit to enable movement, and adenosine is the ‘brake’ that promotes the second circuit and brings balance to the system.”

The discovery could immediately suggest new avenues of drug development to treat symptoms of Parkinson’s disease, a movement disorder where the loss of dopamine-producing cells has been widely implicated as a cause.

Scientists have long suspected  that dopamine is influenced by an opposing dynamic of neuronal signaling in the striatum — a critical region of the brain that mediates movement along with reward, motivation and learning. The striatum is also the primary brain region affected in Parkinson’s disease by the loss of dopamine-producing cells.

“People for a long time suspected there has to be this push-pull system,” said co-author Tianyi Mao, Ph.D., a scientist at the Vollum who happens to be married to Zhong.

In the new study, researchers for the first time clearly and definitively revealed adenosine as the neurotransmitter that acts in an oppositional sense with dopamine. The study, involving mice, used novel genetically engineered protein probes recently developed in the Zhong and Mao labs. An example of that technology was highlighted last month in a study published in the journal Nature Methods.

Notably, adenosine is also well known as the receptor that caffeine acts upon.

“Coffee acts in our brain through the same receptors,” Mao said. “Drinking coffee lifts the brake imposed by adenosine.”

In addition to Zhong and Mao, Lei Ma, Ph.D. of the Vollum Institute is the first author. Co-authors include Julian Day-Cooney, Ph.D., Michael A. Muniak, Ph.D., and Maozhen Qin of the Vollum; and, Omar Jaidar Benavides, Ph.D., and Jun B. Ding, Ph.D., of Stanford University.

This work was supported by two BRAIN Initiative awards to Zhong and Mao through the National Institutes of Health, awards U01NS094247 and R01NS104944; as well as three awards through the National Institute of Neurological Disorders and Stroke of the NIH, award R01NS081071 to Mao and R21NS097856 and R01NS127013 to Zhong.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.